Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Isis Pharmacueticals

- PMLiVE

Roche buys GenMark for $1.8bn to bolster diagnostics portfolio

Swiss pharma company will gain respiratory pathogen panels to strengthen its COVID-19 testing capabilities

- PMLiVE

Rare Disease Day in a COVID-19 environment

For many people and families living with a rare disease, their journey can be very complex. At times, that journey can even be scary, frustrating and confusing. However, when your...

Lucid Group Communications Limited

- PMLiVE

The five-step, rare disease-ready checklist

How can a commercial team find success in the rare disease area?

- PMLiVE

bluebird bio marks Rare Disease Day 2021 with launch of patient testimonial video

Personal stories from nine patients from seven European countries, aged between 4 and 61, shed light on the impact of living with thalassaemia

- PMLiVE

Protalix, Chiesi’s monthly treatment PRX-102 shows benefit in Fabry disease

Fabry disease is a rare disorder in which patients inherit a deficiency of the α–Galactosidase–A enzyme

- PMLiVE

UK introduces Rare Diseases Framework to improve the lives of people with rare diseases

bluebird bio releases a video to raise awareness – Rare Disease Day 2021 is on 28 February

- PMLiVE

Why we need to look at rare diseases in a different way

28 February 2021, Rare Disease Day aims to raise awareness of rare diseases and the impact they have on patients’ lives.

Origins – The Patient Focused Specialists

- PMLiVE

Rare Disease Day – why it’s important to show your stripes

Nucleus Global's EU Strategy Director, Amanda Henkel, writes about the importance of continuing to raise awareness of rare diseases

Nucleus Global

- PMLiVE

Roche’s anti-inflammatory drug reduces deaths in hospitalised COVID-19 patients

Tocilizumab, marketed as Actemra/RoActemra, also reduced time spent in hospital in RECOVERY trial

Roche Basel Switzerland

Roche’s diagnostic business sales offer a bright spot in Q4

Company's pharmaceutical division sales slipped due to biosimilar competition

- PMLiVE

FDA priority review for Roche’s Esbriet in unclassifiable interstitial lung disease

Agency is due to make a decision for the approval by May 2021

- PMLiVE

bluebird bio to separate oncology and rare diseases units

New oncology company will be led by current bluebird bio CEO Nick Leschly

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links